The 2026 Healthtech Messaging Index

Rank#15of 302

BrightInsight

brightinsight.com·scored November 1, 2026

76out of 100

29/38

Approaching

Close. The bones are good. A few targeted fixes on the weakest signals would push BrightInsight into magnetic territory.

ApproachingAI recommends them? No
BrightInsight homepage

The page we scored

The AI Recommendation Check

When we asked AI who to recommend for patient persistence and therapy adherence platform for pharma brands, it named:

Buyer we put in the prompt: VP of Patient Services, Chief Commercial Officer, or Brand General Manager at a large pharmaceutical or biotech company launching or managing a novel therapy. Both the buyer and the category were inferred from BrightInsight’s homepage alone. The model had no web access.

Adheris HealthAktanaLash GroupValidicVeeva SystemsSalesforce Health CloudIQVIA Orchestrated Customer EngagementKomodo Health

BrightInsight was not on the list.

A buyer who asked AI this question got 8 names and moved on. BrightInsight never came up.

We asked AI who it recommends for "VP of Patient Services, Chief Commercial Officer, or Brand General Manager at a large pharmaceutical or biotech company launching or managing a novel therapy" looking for "patient persistence and therapy adherence platform for pharma brands". It named Adheris Health, Aktana, Lash Group, Validic, Veeva Systems. You did not appear. AI can't recommend what it can't clearly understand.

Overall assessment

BrightInsight's biggest strength is its razor-sharp category ownership ... 'patient persistence,' 'persistence crisis,' and 'Leaky Bucket' are coined terms backed by a $500B quantified stake and a named Sanofi outcome, making it highly quotable and distinctively positioned for AI and human buyers alike. The biggest gap is conversion architecture: there is no numbered process, no named alternatives acknowledged, and the only CTA is a generic 'Contact us' with no explanation of what happens next, leaving motivated buyers with no clear path forward.

Signal by category

Narrative Clarity

8 signals

15/16

Trust Signal

4 signals

5/8

AI Signal

6 signals

8/12

Conversion Signal

1 signal

1/2
0

Weakest signal · fix this first

12Alternatives Acknowledged

“No mention of competitors, alternative approaches, or 'do nothing' option anywhere on the page.”

The page never acknowledges what buyers are doing today instead, names any competitor, or addresses the 'do nothing' path, leaving objections completely unaddressed.

All 19 signals, scored 0 to 2.

Narrative Clarity

8 signals

15/16
  • 01The 7-Second Test

    “BrightInsight is the patient persistence solution that predicts and prevents therapy drop-off ... before it happens.”

    Within seconds, a visitor knows the audience (pharma brands), the problem (patients quitting therapy), and the POV (predict and prevent before it happens) ... clear enough for a non-expert.

    2
  • 02Rebellion / Movement

    “the persistence crisis steals health from patients and $500B+ in annual value from brands every year”

    The page explicitly names the status quo enemy ... existing systems that fail to retain patients ... and frames the $500B persistence crisis as the broken industry pattern BrightInsight is rebelling against.

    2
  • 03Owned Language & Category

    “'patient persistence solution,' 'persistence crisis,' 'The Leaky Bucket: The Pharma Industry's Greatest Hidden Threat'”

    BrightInsight owns 'patient persistence' as a named category and coins 'persistence crisis' and 'Leaky Bucket' as proprietary frames an LLM could cite and attribute back to them.

    2
  • 04ICP Clarity

    “brands that reclaim the revenue their science was built to generate”

    The buyer is implied to be a pharma brand executive, but role (e.g., VP of Patient Services, Chief Commercial Officer), company size, and therapy area are never explicitly called out.

    1
  • 05Problem Leadership

    “fewer than 1 in 3 patients still on a novel therapy at 12 months, the persistence crisis steals health from patients”

    The page leads with a stark buyer problem ... patient drop-off and the $500B revenue loss ... framed in the buyer's language before pivoting to the solution.

    2
  • 06Solution Clarity

    “unifies the patient experience, detects the behavioral signals that precede discontinuation, and triggers the right intervention at the moments that matter most”

    A visitor can repeat what BrightInsight does in one sentence: it unifies patient data and triggers timely interventions to prevent therapy drop-off.

    2
  • 07Cost of Inaction

    “$500B+ in annual value from brands every year”

    The cost of inaction is quantified explicitly ... $500B in lost annual brand value plus patients losing health outcomes ... making the stakes concrete and urgent.

    2
  • 08Promised Land

    “patients who stay on therapy longer, and brands that reclaim the revenue their science was built to generate”

    The promised land is stated clearly: longer patient retention, compounding value into year two and three, turning the revenue leak into a growth lever.

    2

Trust Signal

4 signals

5/8
  • 09Proof & Evidence

    “reduced discontinuation by 4% and boosted adherence by 4% in one year for Sanofi”

    The Sanofi outcome provides specific before/after deltas with a named partner and a defined time period ... not adjectives, actual numbers.

    2
  • 10Social Proof

    “Sanofi case study image”

    Sanofi is named with quantified results, and Stanford Health Care is cited with an 80% retention stat, but there are no named testimonials with titles or video stories ... just press release references.

    1
  • 11Authority & Credibility

    “Kal Patel, MD, CEO and Co-Founder, BrightInsight”

    The CEO's MD credential is visibly attached to published thought leadership (blog posts), lending clinical authority that is demonstrated through content, not just claimed.

    2
  • 12Alternatives Acknowledgedweakest

    “No mention of competitors, alternative approaches, or 'do nothing' option anywhere on the page.”

    The page never acknowledges what buyers are doing today instead, names any competitor, or addresses the 'do nothing' path, leaving objections completely unaddressed.

    0

AI Signal

6 signals

8/12
  • 13Customer Focus

    “turn your greatest revenue leak into your most powerful growth lever”

    The page consistently frames the customer (pharma brand) as the protagonist whose revenue, patients, and outcomes are at stake ... BrightInsight is positioned as the enabler, not the hero.

    2
  • 14AI-Parmesan Index

    “detects the behavioral signals that precede discontinuation, and triggers the right intervention at the moments that matter most”

    There are mechanistic descriptions of how the solution works (behavioral signal detection, intervention triggers), but the role of AI/ML is implied rather than named or explained with specificity.

    1
  • 15LLM Quotability

    “fewer than 1 in 3 patients still on a novel therapy at 12 months, the persistence crisis steals health from patients and $500B+ in annual value”

    Multiple clean, declarative, stat-anchored sentences exist that an LLM could lift verbatim to describe the problem and BrightInsight's positioning in this category.

    2
  • 16Copyright Freshness

    “Kal Patel, MD, CEO and Co-Founder, BrightInsight / Sep 09, 2026”

    Dates are visible on blog posts and a 2026 copyright year is implied by the content, but the Sep 09, 2026 date appears to be future-dated, which could undermine recency credibility rather than support it.

    1
  • 17Entity Distinctiveness

    “'patient persistence solution,' 'persistence crisis,' 'The Leaky Bucket,' Sanofi adherence results, Stanford 80% retention”

    The combination of owned terminology, named pharma partner outcomes, and the specific $500B persistence crisis frame makes this company unmistakably distinct ... swapping the logo would break the description.

    2
  • 18AI Recommendation Check

    “AI's picks: Adheris Health, Aktana, Lash Group, Validic, Veeva Systems, Salesforce Health Cloud. You were not named.”

    We asked AI who it recommends for "VP of Patient Services, Chief Commercial Officer, or Brand General Manager at a large pharmaceutical or biotech company launching or managing a novel therapy" looking for "patient persistence and therapy adherence platform for pharma brands". It named Adheris Health, Aktana, Lash Group, Validic, Veeva Systems. You did not appear. AI can't recommend what it can't clearly understand.

    0

Conversion Signal

1 signal

1/2
  • 19Path & CTA Clarity

    “Contact us today to start a conversation”

    There is a soft CTA (Contact Us) and a secondary Learn More link, but no visible numbered process or clear path showing what happens after contact ... the conversion journey is undefined.

    1

Your move

Think BrightInsight’s score is wrong? Good. Let’s look at it together.

Twenty minutes with Greg. Bring the page, bring the argument. You’ll leave knowing exactly which signal is costing BrightInsight the AI recommendation, and what to write instead.

Not on the list? Run your homepage through the free Brand Signal Score and see where you’d land. Same 19 signals, same AI check, two minutes.

← Back to the full Healthtech index

We revamp websites that ChatGPT ignores.

See the 90-Day AI Website Rebuild →